Search

DBV Technologies SA

Suletud

2.6 0.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.5949999999999998

Max

2.64

Põhinäitajad

By Trading Economics

Sissetulek

-15M

-42M

Müük

2.2M

2.2M

Kasumimarginaal

-1,888.814

Töötajad

109

EBITDA

-14M

-39M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+125.56% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

28. okt 2025

Turustatistika

By TradingEconomics

Turukapital

143M

404M

Eelmine avamishind

2.41

Eelmine sulgemishind

2.6

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

DBV Technologies SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2024, 23:55 UTC

Kuumad aktsiad

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

DBV Technologies SA Prognoos

Hinnasiht

By TipRanks

125.56% tõus

12 kuu keskmine prognoos

Keskmine 6 EUR  125.56%

Kõrge 6 EUR

Madal 6 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi DBV Technologies SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.61 / 1.72Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
help-icon Live chat